Zooming in on: Psychological Mechanisms of Psychedelic Therapies | Dr. Leor Roseman

Long-term outcomes of psychedelic interventions appear to depend substantially on the quality of the psychedelic experience. According to most protocols for dosing sessions in contemporary psychedelic therapy research, one individual patient is supported by two guides while lying down with closed eyes and listening to music. This particular setting seems to be conducive to mystical-type and emotional breakthrough experiences, both of which are associated with long-lasting increases in well-being and reductions in psychopathology. What is the psychology behind these experiences and their therapeutic impact? What factors determine their occurrence and intensity? Should we expect different treatment settings to produce different kinds of therapeutic experiences, and thus different outcomes? What unique advantages might group settings provide in this regard? These and other exciting questions will be addressed in this conversation-based webinar with Dr. Leor Roseman. Questions and comments by the audience will be welcome.
This event will be presented by Dr. Max Wolff, a clinical psychologist and member of a study team that is currently preparing a large-scale clinical trial of psilocybin-assisted therapy for treatment-resistant depression in Germany.
About LEOR ROSEMAN
Dr. Leor Roseman is a postdoc at the Centre for Psychedelic Research, Imperial College London, where he also received his Ph.D. and MRes, under the supervision of Dr. Robin Carhart-Harris and Prof. David Nutt. His research is focused on the neural and psychological correlates of the psychedelic experience, and the therapeutic application of psilocybin for treatment-resistant depression. Currently, Leor is investigating psychosocial elements of psychedelics, and focusing on the potential of ayahuasca for peace-building between Palestinians and Israelis.
About the ZOOMING IN Webinar Series
The ZOOMING IN webinar series at the MIND Academy features in-depth conversations with researchers and clinicians involved in the re-emerging field of psychedelic therapy and neighboring disciplines.